factor for sensory fibers, and Semaphorin3C (Sema3C) and Semaphorin3F (Sema3F) repulse sympathetic nerve fibers [6]. Whereas the primary receptor for Sema3A is neuropilin1 (NRP1), Sema3F has a higher binding affinity to neuropilin2 (NRP2). Sema3C binds to both NRP1 and NRP2 [7,8]. The action of Sema3A is not limited to the nervous system as NRP1 is expressed on endothelial cells, keratinocytes, T cells, and tumor cells in breast and prostate cancer. Sema3A inhibits angiogenesis, migration of keratinocytes, proliferation of T cells, and migration of tumor cells [8-11]. In addition, it was recently shown that Sema3A is involved in the entry of dendritic cells to the lymphatic system [12]. Several studies have indicated that a reduction of Sema3A expression is involved in the exacerbation of autoimmune diseases, such as RA and systemic lupus erythematosus (SLE) [13,14]. NRP1 mediates signal transduction through PlexinA coreceptors [15], which are classified into four sub-families, PlexinA1–4 [16]. The Sema3A/NRP1/PlexinA complex regulates the actin cytoskeleton through small G-proteins, including Rac and Rho [17]. In immune cells, the Rac family is associated with the proliferation and activation of B cells [18], and the activation of T cells induced by dendritic cells [19]. NRP1 is also a putative marker of regulatory T cells [20], and therefore Sema3A/NRP1/PlexinA signaling may modulate regulatory T cell functions. Vascular endothelial growth factor165 (VEGF165), a spliced
Hearing and sight loss aren’t an obvious disability so people may not be aware that the individual has this difficulty and may judge them wrongly. A lack of knowledge can lead people to be prejudice and discriminate against the individual. Sometimes people talk down to them as if they are stupid or talk to the person they are with which can make them feel ignored and worthless. It can also have the opposite effect where people want to everything for the
Nevertheless, there is a promising biomarker and therapeutic target on the horizon. Studies show that S100A8 is preferentially overexpressed in ATC3,6, leading to the formation of tumors and invasion of the trachea. Knockdown of this protein, however, abolished tumor formation6. It is thought that S100A8 interacts with the RAGE receptor to promote cell proliferation by activating the p38, ERK 1/2, and JNK signaling pathways2.6. Taken together, this indicates that S100A8 is a potential diagnostic biomarker and that targeting this gene will prevent progression of the
Systemic Lupus Erythematosus (SLE) is a genetic disorder. SLE is a type III hypersensitivity or an autoimmune hypersensitivity (VanMeter, K. C., PhD, & Hubert, R. J., BS, 2014). Meaning that the body is attacking itself. In SLE a large number of autoantibodies circulate through the body (VanMeter, K. C., PhD, & Hubert, R. J., BS, 2014). These autoantibodies are deposited into the connective tissue all over the body (VanMeter, K. C., PhD, & Hubert, R. J., BS, 2014). These autoantibodies activate the complement system and cause inflammation and necrosis of the tissue that the autoantibodies are near (VanMeter, K. C., PhD, & Hubert, R. J., BS, 2014). This usually takes place in many systems in the body. In order to be diagnosed at least four body systems have to be affected.
Signaling pathways that result in cell migration are often useful in understanding how cancer cells metastasize. The researchers of Swaminathan et al., 2016 examine how adhesion site assembly occurs while Nader et al., 2016 focuses primarily on the adhesion turnover both are fundamental processes in cell migration. Integrins play a dominant role in nascent integrin-mediated adhesions (NAs) which are important in lamellipodium protrusion and generating traction at focal adhesion points involved in cell motility. Integrins have been extensively studied and are linked to wound healing as well as metastasis in cancer cells (Lawson et al., 2012). When extracellular signals, either chemical or physical, contact the cell surface it triggers a response that induces movement. If the signaling molecule is a growth factor (ex. Epidermal Growth Factor) it could activate a GTPase protein coupled receptor (GPCR). The next is a signal cascade often led by Rabs or Ras (small G-proteins) proteins that are powered by GTPase hydrolysis, which often recruits and activates Wiskott–Aldrich Syndrome protein (WASP) or Scar. Previous studies identified cancer cell that use Rab-coupling to control cell motility by regulating B-intgrins trafficking (Nader et al., 2016). WASP recruits Actin related protein 2 and 3 (Arp2/3) complex to the cell membrane and activates it
Eotaxin-2 is able to function as a chemotactic chemokine for resting t-lymphocytes, and eosinophils. Eotaxin-2 has lower
Systemic lupus erythematosus (SLE) is a chronic inflammatory and autoimmune disease of multifactorial etiology that can affect many organs and systems (Sato, 2002).
Sensory Processing Disorder is a condition in which the brain has the difficulty in receiving and responding to information that comes in through all seven senses in daily life.
One of the most important receptors in cell signalling is the trimeric (sinq kniga 596)G protein coupled receptor (GPCR). That is a receptor which has a surface part and an intracellular part (composed of 3 subunits a;b;y). GPCR pathway leads to the activation of another pathway group ERK (extracellular signal regulated kinases). This complex pathway is also regulated by phosphorylation (sinq kniga cell biology).
Sensory Processing Disorder in infants and toddlers is the level of difficulty the infant has with registering, integrating and processing during the developmental stages of the child’s fine motor skills. This also affects social skills and perceptual/cognitive abilities. The infant or child with sensory processing disorder will either experience hypensitivity in regards to being over responsive or will be on the other end of the spectrum experiencing under responsive sensory processing. Activities in the early developmental stage that provide important sensory processing experiences are playing with toys, being held with breastfeeding, taking baths or going to the park.
Millions of people around the world suffer from incurable, autoimmune diseases. Even with the tremendous advancement in medical field, there are many questions unanswered. More and more diseases of unknown cause are being evolved every now and then, which are threatening to the mankind. Systemic lupus erythematosus (SLE) is a classic example of such a disease. SLE is a chronic, often life-long, autoimmune condition, ranging from mild to severe in severity. SLE may affect many organs in the body, including but not limited to kidneys, skin, joints, respiratory and nervous systems. The name of this disease describes it; word systemic indicates the widespread involvement of various tissues and organs of the body. Lupus is a word derived from Latin language, which means wolf, referring to the rash on the face which was thought to resemble a wolf bite. Erythematosus is a Greek word, meaning red, referring to the color of the rash.
Whilst some mechanisms have been widely demonstrated, others have not. The pathways that link the P2X7 receptor to IL-1β and IL-18 production and activation for example have been substantiated by many studies. What is not so clear however is the mechanism in which they are released. Many proposals have been proclaimed yet evidence pointing toward a standalone action remains elusive. Other interleukin-1 cytokines have also been linked to P2X7 activity and these also hold their own mysteries. How different is the biological activity of pro-IL1α and IL-1α for example? What mechanism is responsible for IL-1α secretion? How is the release of IL-1Ra and IL-36α linked to the release of IL-1β, IL-18 and IL-1α? Is there evidence that other interleukin-1 cytokines are linked to the P2X7 receptor but have not yet been concluded? This project will scrutinize the current literature available to answer such questions. Finding the answers and revealing some of the unknown mechanisms causing IL-1 activation and release could be imperative in developing new treatments for a number of inflammatory diseases or
Abstract: Selectins are carbohydrate-binding proteins that play a vital role in inflammatory responses. These proteins are involved in the homing of leukocytes and have been implicated in numerous diseases, including autoimmune diseases such as multiple sclerosis as well as various form of cancer. In addressing the role of selectins in autoimmune diseases, it has been found that they involved in the trafficking of immune cells to secondary lymphoid organs under normal conditions as well as to peripheral tissues during inflammation. Precise selectin–ligand interactions facilitate the recruitment of distinct immune cell subpopulations in specific target organs during autoimmune diseases. Additionally, selectins (and their ligands) are also vital for homeostasis and immune cell activation. Tissue-specific, selectin antagonists are fairly promising new therapeutic approaches for the treatment of autoimmune and inflammatory diseases, however, a more precise mechanism for selectin leukocyte targeting must be uncovered first. Selectins also have been found to translate their roles in cellular adhesion to metastatic progression when the correct ligand is present. Though selectins have been identified as potential facilitators of metastasis, they have not been studied as drug targets for treating cancer progression and metastasis. However, targeting selectins as a cancer metastasis treatment could prove very successful as seen from initial positive clinical findings regarding heparin
CXCR3 attract the NK cells located at the surface of tissue that later act as IL-17 and induce inflammatory cytokine production and that can lead to tumor angiogenesis .
Indeed, it has been identified that PARs, in general, implicate in the activation of different cytokines in the cell, and mediate responses that are mainly leading to inflammation, pain, swelling, and redness. The Study done on the rat cortex by using PAR4 activating peptide showed that this PAR4 agonist (AP GYPGKF) raise the TNF-α expression which enhances inflammation in human cells. In addition to their pathological roles, PARs also have been recorded in mediating cancer progression. Different current studies identified that expression of PAR4 is highest in prostate cancer, and it also mediates the migration of colon cancer and hepatocellular carcinoma-derived cell lines [4]. However, in the cancer targeting strategy, some researchers use
Extra-cellular stimuli trigger intra-cellular signaling pathways, which in turn upregulate ATF3. For instance, the p38 MAPK pathway is necessary for various signals (such as anisomycin, IL-1β (interleukin 1β), TNFα (tumour necrosis factor α) and H2O2 to induce ATF3. Prostaglandin induction of ATF3 in the bovine corpus luteum is inhibited by inhibitors of the ERK, JNK and p38 MAPK pathways. Various other pathways are also linked with ATF3 induction such as the Smad, Myc, Ras and NF- pathways (Review). In fact, a review of existing literature clearly underlines one feature of ATF3 induction: it is neither tissue-specific nor stimulus specific. ATF3 is induced in many different cell types, both in vivo and in vitro, by many different extra-cellular and